Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Dexamethasone Eye Drops in Preterm Infants With ROP
NCT05387941Phase 1Completed
- Sponsor
- Region Skåne
- Start
- Jun 2022
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dexamethasone in retinopathy of prematurity (ROP), sponsored by Region Skåne. Primary endpoints: Half-life of plasma concentrations of dexamethasone at 14 weeks, Maximum plasma concentration of dexamethasone at 14 weeks and 7 more. Started Jun 2022; status: completed.
02
Drugs
dexamethasone
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT05387941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387941.